LIVERATION is a comprehensive, practical, and multinational clinical trial spanning seven countries, in the order to investigating if the enlargement of the ablated margin through radiofrequency can reduce the recurrence of Colorectal Cancer Liver Metastasis and enhance patient longevity in both, Colorectal Cancer Liver Metastasis, as well as in Liver Cancer patients.
Colorectal cancer is the third most common tumour in men and the second in women, with an forecast of 1.9 million new cases worldwide (450K in Europe) and approximately 900,000 deaths in 2020. Hepatic metastases develop in around 50% of colorectal cancer cases.
Furthermore, the liver is the first and only area of spread in 30–40% of patients. Surgery is considered the gold standard treatment and the only potentially curative option for colorectal liver metastases.